Account

Sign in to access your account and subscription

An Alternative: Making Drugs Affordable

The Pharmaceutical Research and Manufacturers of America reported on Feb. 22 that a record number of patients received free or discounted medications from America's pharmaceutical companies last year as part of an industry initiative to help low-income consumers access the medications they need. "PhRMA member companies know a medication that sits on a shelf, out of financial reach of patients, helps no one," said Billy Tauzin, president and chief executive officer of PhRMA. Under these programs, consumers received more than 22 million prescriptions with a wholesale value of $4.17 billion in 2004, up from 18 million prescriptions with a value of $3.4 billion in 2003.

3 minute read March 30, 2005 at 11:00 AM
By
Law.com Staff
An Alternative: Making Drugs Affordable

The Pharmaceutical Research and Manufacturers of America reported on Feb. 22 that a record number of patients received free or discounted medications from America's pharmaceutical companies last year as part of an industry initiative to help low-income consumers access the medications they need.

This premium content is locked for LawJournalNewsletters subscribers only

ENJOY UNLIMITED ACCESS TO THE SINGLE SOURCE OF OBJECTIVE LEGAL ANALYSIS, PRACTICAL INSIGHTS, AND NEWS IN LawJournalNewsletters

  • Stay current on the latest information, rulings, regulations, and trends
  • Includes practical, must-have information on copyrights, royalties, AI, and more
  • Tap into expert guidance from top entertainment lawyers and experts

Already have an account? Sign In Now

For enterprise-wide or corporate access, please contact Customer Service at [email protected] or call 1-877-256-2473.

NOT FOR REPRINT

© 2026 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Continue Reading

The Copyright Royalty Board (CRB), which works under the umbrella of the Librarian of Congress, sets statutory-license royalty terms and rates. The U.S. Courts of Appeals for the D.C. Circuit recently issued two notable decisions about the CRB.

October 01, 2026